An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Axonics® to Participate in September Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Axonics, Inc. (NASDAQ: AXNX), headquartered in Irvine, California, has announced its participation in key investor conferences. Senior management will present at the Wells Fargo Healthcare Conference on September 8, 2022 at 10:25 a.m. ET, followed by the Morgan Stanley Healthcare Conference on September 12, 2022 at 11:05 a.m. ET. Interested investors can access the live and archived webcasts on the Axonics investor relations website.
Positive
None.
Negative
None.
IRVINE, Calif.--(BUSINESS WIRE)--
Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that senior management is scheduled to present at the following investor conferences:
Event: Wells Fargo Healthcare Conference Date: Thursday, September 8, 2022 Time: 10:25 a.m. Eastern Time
Event: Morgan Stanley Healthcare Conference Date: Monday, September 12, 2022 Time: 11:05 a.m. Eastern Time
Interested parties may access a live and archived webcast of each presentation by visiting the Axonics investor relations website.
About Axonics
Based in Irvine, Calif., Axonics is a global medical technology company that is developing and commercializing novel products for adults with bladder and bowel dysfunction. Axonics recently ranked No. 1 on the 2021 Deloitte Technology Fast 500™ and the 2022 Financial Times ranking of the 500 fastest growing companies in the Americas.
Axonics sacral neuromodulation (SNM) systems provide patients suffering from overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, the company’s best-in-class urethral bulking hydrogel, Bulkamid®, provides safe and durable symptom relief to women with stress urinary incontinence (SUI). Overactive bladder affects an estimated 87 million adults in the U.S. and Europe, with an additional 40 million adults estimated to suffer from fecal incontinence. SUI affects an estimated 29 million women in the U.S. alone. Axonics’ clinically proven products are offered at hundreds of medical centers across the U.S. and abroad. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries. For more information, visit www.axonics.com.
What is Axonics presenting at the Wells Fargo Healthcare Conference?
Axonics will present at the Wells Fargo Healthcare Conference on September 8, 2022, at 10:25 a.m. ET.
When will Axonics participate in the Morgan Stanley Healthcare Conference?
Axonics will participate in the Morgan Stanley Healthcare Conference on September 12, 2022, at 11:05 a.m. ET.
Where can I watch Axonics' investor presentations?
You can watch Axonics' presentations live and on-demand via the Axonics investor relations website.
What products does Axonics develop for bladder dysfunction?
Axonics develops sacral neuromodulation systems and urethral bulking hydrogel for treating bladder and bowel dysfunction.
What is the significance of Axonics' ranking by Deloitte?
Axonics was ranked No. 1 on the 2021 Deloitte Technology Fast 500 and featured in the 2022 Financial Times ranking of the fastest growing companies in the Americas.
